JTJia‐Li Tao

Jia‐Li Tao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia‐Li Tao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ziming Huang

    Department of Emergency Surgery, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu, China,

    3 shared publications
  • Chen‐Chen Yang

    Department of Emergency Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China

    1 shared publication
  • Heng‐Fa Ge

    Department of Emergency Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China

    1 shared publication
  • Hong Sun

    Department of Emergency, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu, China,

    1 shared publication
  • Hong Sun

    Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Hongmei Zhao

    Department of Emergency, The Affiliated Huaian No 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu, China,

    1 shared publication

Latest Publications

  • Open Access

    Overexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling

    by Jia‐Li Tao, Man Luo, Hong Sun, Hong‐Mei Zhao, Qing‐Song Sun, Zi‐Ming Huang

    It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.


  • Open Access

    MicroRNA‐26a‐5p inhibits breast cancer cell growth by suppressing RNF6 expression

    by Zi‐Ming Huang, Heng‐Fa Ge, Chen‐Chen Yang, Yong Cai, Zhen Chen, Wen‐Ze Tian, Jia‐Li Tao

    MicroRNA‐26a‐5p (miR‐26a‐5p) has been reported to be involved in the tumorigenesis of several tumors, but its function in breast cancer is still unknown. In this study, miR‐26a‐5p was found significantly downregulated in both of the breast cancer tissues and cell lines, and low expression of miR‐26a‐5p predicted a poor prognosis for breast cancer patients. Overexpression of miR‐26a‐5p could significantly inhibit breast cancer cell growth. Further studies revealed that overexpression of miR‐26a‐5p downregulated the protein levels of Cyclin D1, CDK4, and CDK6, but upregulated the expression levels of p21, p27, and p53. In mechanism, miR‐26a‐5p targeted the 3′UTR of ring finger protein 6 (RNF6) mRNA and inhibited RNF6 expression in breast cancer cells. Moreover, overexpression of miR‐26a‐5p inhibited RNF6/ERα/Bcl‐xL axis in breast cancer cells. In contrast, inhibiting miR‐26a‐5p upregulated RNF6/ERα/Bcl‐xL axis. Further studies indicated that miR‐26a‐5p mediated RNF6/ERα/Bcl‐xL axis through regulating the stability of ERα protein. Collectively, downregulation of miR‐26a‐5p plays essential roles in breast cancer by mediating RNF6/ERα/Bcl‐xL axis, which might provide important implications for the therapeutics of breast cancer.


  • Open Access

    The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma

    by Jiali Tao, Hongmei Zhao, Xiaochen Xie, Man Luo, Zhiwei Gao, Hong Sun, Ziming Huang

    Background and objectives: The nuclear factor kappa B (NF-κB) signaling is activated in esophageal squamous cell carcinoma (ESCC) and can be used as a potential target for anti-ESCC drug discovery. In this study, we aimed to investigate the function of flubendazole as a novel NF-κB inhibitor in ESCC cells. Materials and methods: Cell Counting Kit-8 assay was carried out to assess cell viability of ESCC cells. Flow cytometry and immunoblotting were performed to examine cell apoptosis. Immunoblotting assay was used to analyze the protein expression of NF-κB signaling. Luciferase assay was performed to explore the activation of NF-κB. Plasmids were transfected into ESCC cells using Lipofectamine® 2000. Results: In this study, the anthelmintic drug flubendazole was found to inhibit the activation of IκBα kinases (IKKs), block the activation of IκBα, and decrease the phosphorylation of NF-κB p65, which could be a novel NF-κB inhibitor in ESCC cells. We also found that flubendazole inhibited the cell survival of different ESCC cells and induced cell apoptosis in both EC9706 and TE1 cells. Moreover, overexpression of constitutively activated IKKβ markedly decreased the cytotoxic effect of flubendazole on EC9706 and TE1 cells. In addition, flubendazole also showed a synergistic effect on ESCC cells when combined with doxorubicin. Conclusion: The results above demonstrated that flubendazole showed its anti-tumor action by suppressing the NF-κB signaling pathway and suggested that flubendazole might be re-purposed for anti-ESCC therapy in clinic as a single agent or in combination with other anti-tumor drugs.